4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

Catalog No. :
ACYHAM345
CAS No. :
214360-73-3
Molecular Formula :
C12H18BNO2
Molecular Weight :
219.09

IUPAC Name:4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100g98%$106.00Login to see priceIn stockInquiry
500g98%$501.00Login to see priceIn stockInquiry
1000g98%$939.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
IUPAC Name4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
MDL No.MFCD02093721
Molecular FormulaC12H18BNO2
Molecular Weight219.09
SMILESC1=C(C=CC(=C1)N)B2OC(C(O2)(C)C)(C)C
InChI KeyZANPJXNYBVVNSD-UHFFFAOYSA-N
Synonym(4-Aminophenyl)boronic acid, pinacol ester | 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline | 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-aniline | 4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)aniline | Pinacol cyclic ester | RB3075 | 4-Am
CAS No.214360-73-3
PubChem CID2734620

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACYHAM345 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNWSC905 route compound structure diagram
    ACNWSC905330793-01-6 In Stock
  2. Then
  3. ACYHAM345 route product structure diagram
    ACYHAM345214360-73-3 In Stock
Inquiry

2. ACYHAM345 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACYHAM345 route product structure diagram
    ACYHAM345214360-73-3 In Stock
Inquiry

Comments (0)